دورية أكاديمية
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.
| العنوان: | Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. |
|---|---|
| المؤلفون: | van Griensven, Johan, Edwards, Tansy, de Lamballerie, Xavier, Semple, Malcolm G, Gallian, Pierre, Baize, Sylvain, Horby, Peter W, Raoul, Hervé, Magassouba, N'Faly, Antierens, Annick, Lomas, Carolyn, Faye, Ousmane, Sall, Amadou A, Fransen, Katrien, Buyze, Jozefien, Ravinetto, Raffaella, Tiberghien, Pierre, Claeys, Yves, de Crop, Maaike, Lynen, Lutgarde, Bah, Elhadj Ibrahima, Smith, Peter G, Delamou, Alexandre, de Weggheleire, Anja, Haba, Nyankoye |
| المساهمون: | Institute of Tropical Medicine Antwerp (ITM), MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine (LSHTM), Aix Marseille Université (AMU), Institut de Recherche pour le Développement (IRD France-Sud ), École des Hautes Études en Santé Publique EHESP (EHESP), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Etablissement Français du Sang La Plaine Saint-Denis (EFS), Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur Paris (IP), Centre for Tropical Medicine and Global Health Oxford, UK, Nuffield Department of Medicine Oxford, UK (Big Data Institute), University of Oxford-University of Oxford, Laboratoire P4 - Jean Mérieux, Centre Européen de Virologie/Immunologie-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire des Fièvres Hémorragiques en Guinée, Université Gamal Abdel Nasser de Conakry, Médecins Sans Frontières Belgique, Institut Pasteur de Dakar, Réseau International des Instituts Pasteur (RIIP), Clinical Pharmacology and Pharmacotherapy Leuven, Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang Bourgogne-Franche-Comté (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC), Hôpital National Donka, Centre National de Formation et de Recherche en Santé Rurale Maférinyah, Guinée (CNFRSR), National Blood Transfusion Center, ANR-10-INBS-0006,HIDDEN,Extension de l'infrastructure de recherche dédiée aux maladies hautement infectieuses(2010) |
| المصدر: | ISSN: 0028-4793. |
| بيانات النشر: | HAL CCSD Massachusetts Medical Society |
| سنة النشر: | 2016 |
| المجموعة: | Institut Pasteur: HAL |
| مصطلحات موضوعية: | [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology |
| الوصف: | International audience ; In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26735992; hal-01252702; https://hal.science/hal-01252702Test; PUBMED: 26735992; PUBMEDCENTRAL: PMC5856332 |
| DOI: | 10.1056/NEJMoa1511812 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa1511812Test https://hal.science/hal-01252702Test |
| رقم الانضمام: | edsbas.498B6300 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/NEJMoa1511812 |
|---|